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Background
Only a few patients who experience AML relapse derive lasting benefit from re-induction 
therapy. The utility of reassessing the disease karyotype at relapse is unclear. The main 
goals of this study were to identify prognostic factors for AML relapse and to determine 
the prognostic utility of karyotypic change between diagnosis and relapse as a variable 
for predicting response to salvage therapy for relapsed AML. 
Methods
This retrospective study included 58 patients with relapsed AML treated at the Yonsei 
University College of Medicine between 2005 and 2010. Karyotypes at both diagnosis 
and relapse were available for 45 patients (77%). A change in karyotype at relapse was 
observed in 17 of 45 cases (37%), and no change was noted in 28 of 45 cases (62%). 
Results
Karyotypic changes between diagnosis and relapse were associated with the response 
rate (RR) to salvage therapy (P=0.016). Overall survival (OS) and event-free survival (EFS) 
in the group with karyotypic changes between diagnosis and relapse were significantly 
different from those with no karyotypic changes (P=0.004 and P=0.010, respectively). 
We applied multiple multivariate Cox regression analyses to identify independent prog-
nostic factors for overall response (OR), OS, and EFS. A change in karyotype between 
diagnosis and relapse was significantly associated with OS (P=0.023; RR=2.655) and 
EFS (P=0.033; RR=2.831). 
Conclusion
Karyotypic changes between the diagnosis and relapse of AML could be used to predict 
outcomes and tailor clinical and biological therapeutic strategies for relapsed AML 
patients.
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INTRODUCTION
Most AML patients who achieve a complete remission 
(CR) experience relapse within 3 years of the primary 
diagnosis. The prognosis of patients after relapse is generally 
poor [1], and there is no widely approved salvage regimen 
for AML relapse [2]. Prediction of prognosis at the time 
of relapse would therefore be useful. Important predictors 
of response to re-induction chemotherapy include duration 
of first remission; age at relapse; prior stem cell trans-
plantation; and cytogenetic findings, especially chromosomal 
changes, at initial diagnosis [1]. Among patients who relapse, 
up to 90% with a favorable karyotype at diagnosis achieve 
secondary complete remission (CR2), whereas the CR2 rate 
can be as low as 36% among patients with adverse karyotypes 
at diagnosis [3]. Information regarding karyotype and re-
mission rates is used to modify both the intensity and nature 
of salvage therapy.
Genomic instability may play a role in the development 
of resistance to anti-leukemic therapy. After relapse, leuke-
mic cells are often refractory to standard chemotherapeutic 
agents, and consequently, more aggressive therapies are 
needed to treat this resistant disease [2]. Resistance to therapy 
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in ALL patients may be affected by acquired additional kar-
yotypic abnormalities in the leukemic cells during relapse 
[4]. Although some studies have shown that karyotypic pro-
gression at AML relapse predicts a poor prognosis after sal-
vage chemotherapy [5], the utility of reassessing the kar-
yotype at relapse is unclear.
In this study, we reviewed the data of 58 patients with 
relapsed AML who received salvage therapy. The main goals 
of this study were to identify prognostic factors for relapsed 
AML and to provide evidence for the prognostic utility of 
karyotypic changes between diagnosis and relapse as a varia-
ble for predicting response to salvage therapy for relapsed 
AML.
MATERIALS AND METHODS
Patients
Fifty-eight adult patients with relapsed AML treated at 
the Division of Hematology, Severance Hospital, Yonsei 
University College of Medicine, between January 2005 and 
December 2010 were included in this study. Written in-
formed consent was obtained from each patient. Diagnosis 
of AML was established on the basis of bone marrow (BM) 
aspiration findings. AML was classified according to the mor-
phological French-American-British (FAB) criteria, and the 
diagnosis was confirmed on the basis of cytochemical and 
immunological analyses findings [6]. At diagnosis and relapse, 
samples of BM or blood were examined for cytogenetic ab-
normalities using standard banding techniques and were clas-
sified according to the International System for Human 
Cytogenetic Nomenclature [7]. Cytogenetic analysis was suc-
cessfully performed for 54 of 58 patients (93%) at diagnosis 
and for 48 of 58 patients (82%) at relapse. Karyotypes were 
classified as favorable (t(8;21), chromosome 16 abnormal-
ities), adverse (complex karyotype, -7, 3q abnormality, 
del(5q), -5, 11q23), or intermediate (no abnormality, +8, 
+21, del(7q), del(9q), +22, with other numerical and struc-
tural abnormalities) according to the MRC AML 10 study 
[8]. Induction therapy with idarubicin (IDA) (12 mg/m2/d 
intravenous [IV] over 30 min on days 1–3) in combination 
with cytosine arabinoside (Ara-C) (100 mg/m2/d IV con-
tinuous infusion on days 1–7) was administered to all patients, 
except for 1, who received mitoxantrone, etoposide, and 
cytarabine (MEC)-based chemotherapy (mitoxantrone, 12 
mg/m2/day on days 1–4; etoposide, 100 mg/m2/day on days 
1–3; and Ara-C, 1,000 mg/m2/12 hr on days 1–3). As salvage 
therapy, 40 patients received MEC-based chemotherapy with 
or without gemtuzumab ozogamicin (GO) (90 mg/m2 on 
day 4), 13 patients received other intensive combination 
chemotherapy (Ara-C, topotecan, and IDA, N=5; fludarabine, 
IDA, and Ara-C: N=4; IDA and Ara-C: N=2; and GO: N=1), 
and the remaining 5 patients received allogeneic hema-
topoietic stem cell transplantation (HCT). To determine the 
impact of salvage therapy on relapsed AML, patients were 
classified into prognosis subsets according to the new 
European Leukemic Net (ELN) recommendations, recently 
proposed by an expert panel [1].
Definition of response and relapse
CR was defined as normal cellular BM with normal eryth-
roid and myeloid elements and less than 5% myeloblasts 
and normalization of peripheral blood counts (neutrophils 
＞1×109/L and platelets ＞100×109/L). CR with incomplete 
platelet recovery (CRp) was defined according to the same 
criteria for CR but with additional platelet transfusion in-
dependence and platelet counts of ＜100×109/L. CR and CRp 
cases were considered in the computation of the overall 
response (OR). All other types of responses were considered 
as treatment failure. Relapse was defined as the detection 
of at least 5% leukemic blasts in BM aspirates or new extra-
medullary (EM) leukemia in patients with previously docu-
mented CR [9].
Statistical analysis
Descriptive statistics are reported as frequencies or me-
dians and ranges. OR, overall survival (OS), and event-free 
survival (EFS) were the primary endpoints. The χ2 test was 
used to test for factors associated with OR. Survival was 
calculated from the date of the documentation of relapse 
until death or last follow-up for OS or until failure, relapse, 
death, or last follow-up for EFS. OS and EFS were estimated 
using the Kaplan-Meier product limit method. The following 
factors were analyzed for their association with OR, OS, 
and EFS: age at relapse, type of AML (de novo vs. secondary), 
EM involvement at diagnosis, cytogenetic findings at diag-
nosis and relapse, number of induction cycles of chemo-
therapy required to achieve the first CR, previous HCT, 
relapse-free interval (RFI), type of salvage regimen, and kar-
yotypic changes between diagnosis and relapse. The relation-
ships between patient and disease characteristics and clinical 
outcomes were evaluated using multivariate analysis. OR 
was analyzed using multivariate logistic regression analysis, 
and OS and EFS were analyzed using Cox’s proportional 
hazard model. P values were two-tailed and considered stat-
istically significant if ＜0.05. All factors associated with a 
P  value of ＜0.20 in univariate analysis were entered into 
multivariate analyses. The final analysis was performed using 
SPSS Inc., 12.0 (Chicago, IL, USA).
RESULTS
Changes in karyotype
Karyotype records at both diagnosis and relapse were avail-
able for 45 patients (77%). A change in karyotype was ob-
served in 17 out of 45 cases (37%, group 1) and no change 
was noted in 28 out of 45 cases (62%, group 2). Karyotypic 
changes between diagnosis and relapse in group 1 are shown 
in Table 1. An intermediate karyotype at diagnosis changed 
to a complex karyotype at relapse in 8 cases (47%). Favorable 
karyotypes (2 cases of t(8;21) and 1 of inv(16)) at diagnosis 
changed to normal karyotypes at relapse in 2 cases and were 
the same aberrant karyotypes as at initial diagnosis but with 
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Table 1. Karyotypic change between diagnosis and relapse in AML cases.a)
Karyotype at diagnosis Karyotype at relapse
  1 46, XX [19] 44–45, XX, -8, -9, -22 [cp8]/46, XX [5]
  2 46, XX, t(3; 9; 22) (p23; q34; q11), t(8; 17) (p22; p12) [14] 46, XX, t(1; 10) (p34.2; p13), t(3; 8) (p21; q31), del(7) (q22), t(9; 22) 
(q34.1; q11) [14]
  3 48, XX, +8, +13 [8]/47, XX, +8 [8] 47, XX, +8 [3]/46, XX [5]
  4 46, XX [10] 46, XX, +der(1) t(1; ?) (p13; ?), -2, t(9; 22) (q34; q11.2), der(12), t(12; 17) 
(p13; q11), -17, add(19) (q13.3), +mar [19]/46, XX [1]
  5 45, XY, der(1; 4) t(1; 4) (p12; p16), ins(1; ?) (p12; ?), 
add(3) (p25), 13, +mar [7]/44, idem, dic(16; 19) (p13.3; 
q13.4) [10]/46, XY [1]
41–44, XY, der(1; 4) t(1; 4) (p12; p16), ins(1; ?) (p12; ?), add(3) (p25), -13,
add(14) (p11.1), add(14) (p11.1), add(19) (q13.2), add(20) (q13.2), 
+mar [cp7]/46, XY [21]
  6 46, XY [20] 47, XY, der(1; 7) (q10; p10), +8, der(11; 17) (q10; q10), add(16) (q24) [14]
  7 46, XX, add(7) (q35), t(8; 21) (q22; q22) [9]/46, XX [11] 46, XX [22]
  8 46, XY, t(6; 9) (p23; q34) [20] 46, XY [20]
  9 46, XX, inv(16) (p13q22) [20] 46, XX [21]
10 47, XX, +8 [10]/46, XX [10] 47, XX, +8 [3]/47, idem, add(1) (p36.2) [1]/47, idem, dup(1) (q23q32) 
[1]/47, idem, der(6) t(1; 6) (q25; p23) [2]/47, idem, t(15; 17) (q15; p13) 
[1]/46, XX [16]
11 45, X, -Y, inv(8) (q22q24.3) t(8;21) (q22; q22) [20] 46, XY, t(1; 11) (p36; q13), add(4) (p14), inv(8) (q22q24.3) t(8; 21)
12 46, XX, t(11; ?) (q23; ?) [5]/46, XX [17] 48–51, XX, +6, +8, +8, t(9; 11) (p22; q23), +13, +19 [cp15]/46, XX [5]
13 46, XY [20] 45, XY, der(4) t(4; 15) (p16; q11.1), -15, 1dmin [5]/46, XY [6]//46, XX [3]
14 46, XX, del(2) (p14), +11, der(12) t(6; 12) (p10; q10), -13, 
r(17) (p13q25)
46, XX, der(2) del(2) (p11.2) t(2; 17) (p11.2; q24), der(5) t(5; 13)
15 45, XY, del(6) (q24), inv(9) (p13q21)c, t(16; 21) (p11; 
q22), -19 [20]
45, XY, t(1; 11) (p35; p15), del(6) (q24), inv(9) (p13q21)c, -16, t(16; 21)
16 46, XX, t(11; 19) (q23; p13.1) [20] 46, XX, del(4) (q28), t(11; 19) (q23; p13.1) [17]
17 46, XY [27] 46, XY, t(1; 3) (p32; q22) [8]/46, XY [10]
a)Only cases with karyotypic changes between diagnosis and relapse are shown.
additional aberrations at relapse in 1 case. Adverse karyotypes 
at diagnosis changed to complex karyotypes in 3 cases, and 
a translocation involving 11q23 changed to a normal kar-
yotype in 1 case.
Classification of patients according to karyotypic change be-
tween diagnosis and relapse
We enrolled 31 male and 27 female patients, with a median 
age at diagnosis of 49 years (range, 17–76 years) and a median 
follow-up duration from relapse of 14.3 months (range, 0.2–
149.0 months). Patient characteristics of groups 1 and 2 are 
summarized in Table 2. In group 1, all patients had de novo 
AML, and AML was significantly more prevalent in group 
1 than in group 2 (71.4%, P=0.016). The frequencies of 
cytogenetic changes at relapse were significantly different 
between the 2 groups (P＜0.001), although both groups were 
comparable in terms of the karyotype classification, or the 
cytogenetic risk, at diagnosis. In group 1 at relapse, 1 patient 
(5.9%) had a favorable karyotype, 5 patients (29.4%) had 
an intermediate karyotype, and 11 patients (64.7%) had an 
unfavorable karyotype. In group 2, 3 patients (10.7%) had 
a favorable karyotype, 22 patients (78.5%) had an inter-
mediate karyotype, and 3 patients (10.8%) had an unfavorable 
karyotype. In group 2, 23 (82%) patients received HCT before 
relapse, compared to only 5 patients (52.9%) in group 1 
(P=0.036). Cut-off points for age and RFI were chosen on 
the basis of the mean values in all patients. The 2 groups 
did not show statistical differences in age (＜49 vs. ≥49 
years), sex, FAB classification, white blood cell count at 
diagnosis (＜100 vs. ≥100×109/L), EM involvement at diag-
nosis, type of salvage therapy, number of induction cycles 
required to reach first CR and relapse, or RFI (＜7.5 vs. 
≥7.5 months).
OR, OS, and EFS
Clinical, biological, and treatment-related data were ana-
lyzed to establish whether they had prognostic value with 
respect to OR, OS, and EFS. The OR (CR and mCR) rate 
was significantly lower in group 1 than in group 2 (23% 
vs. 38%; P=0.016). Univariate analysis showed that the cyto-
genetic risk at relapse (P=0.030) and the type of salvage 
therapy (P=0.039) were associated with OR (Table 3). 
Fig. 1 shows Kaplan-Meier curves for OS and EFS. Patients 
in group 1 had a shorter median OS (14.2 vs. 21.1 months, 
P=0.004) and shorter median EFS (4.1 vs. 6.0 months, P= 
0.010) than those in group 2. Age at relapse (P=0.033) and 
type of salvage therapy (P=0.044) were significantly asso-
ciated with OS, and the type of AML (de novo vs. secondary) 
(P=0.025) and cytogenetic risk group at relapse (P=0.028) 
were associated with EFS (Table 3). We also applied multiple 
multivariate Cox regression analyses to identify independent 
prognostic factors for OR, OS, and EFS. Karyotypic change 
between diagnosis and relapse was the only independent 
predictor of OS (P=0.023; response rate [RR]=2.655) and 
EFS (P=0.033; RR=0.033) that retained significance (Table 
4).
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Table 2. Characteristics of patients according to karyotypic changes between diagnosis and relapse.
Group 1a) 
17
Group 2b) 
28 P
Age at relapse, years
    ＜49 vs. ≥49             7 vs. 10           10 vs. 18 NS
Gender
    Male vs. Female             7 vs. 10           18 vs. 10     0.130
Type 
    De novo (%) vs. Secondary (%)  17 (100) vs. 0 20 (71.7) vs. 8 (28.6)     0.016
ECOG performance status
    0–1 vs. ≥2           17 vs. 0           28 vs. 0 NS
Cytogenetic findings at diagnosis
    Fav. and Int. (%) vs. Unfav. (%) 11 (64.8) vs. 6 (35.2) 25 (89.2) vs. 3 (10.8) NS
Cytogenetic findings at relapse
    Fav. and Int. (%) vs. Unfav. (%)   6 (35.2) vs. 11 (64.8) 25 (89.2) vs. 3 (10.8) ＜0.001
WBC, ×109/L
   ＜100 (%) vs.≥100 (%) 14 (82.4) vs. 3 (17.6) 25 (89.3) vs. 3 (10.7) NS
FAB
    M1, 2, 4 (%) vs. M5 (%) 16 (94.1) vs. 1 (5.9) 26 (92.9) vs. 2 (7.1) NS
EM involvement
    Yes (%) vs. No (%) 15 (88.2) vs. 2 (11.8)   2 (92.9) vs. 2 (7.1) NS
HCT before relapse
    Yes (%) vs. No (%)   9 (52.9) vs. 8 (47.1) 23 (82.1) vs. 5 (17.9)     0.036
No. of induction cycles to achieve CR1
    0–1 (%) vs.≥2 (%) 13 (76.5) vs. 4 (23.5) 25 (89.3) vs. 3 (10.7) NS
Salvage regimen
    MEC (%) vs. Ara-C/Anthra-based and others (%) 12 (70.5) vs. 5 (29.5) 20 (71.4) vs. 8 (28.6) NS
OR after salvage therapy
    CR and CRp vs. others 11 (64.7) vs. 6 (35.3) 18 (64.3) vs. 10 (35.7) NS
RFI from CR1, months (mean±SD)          7.58±5.71        10.78±15.24 NS
Median survival, months (mean±SD)        14.24±21.17        21.17±17.64     0.004
a)Cases with changed karyotypes between diagnosis and relapse; b)Cases with unchanged karyotypes between diagnosis and relapse.
Abbreviations: FAB, French-American-British classification; EM, extramedullary; WBC, white blood count; Fav., favorable; Int., intermediate; 
Unfav., unfavorable; No., number; OR, overall response; CR, complete response; CRp, CR with incomplete platelet recovery; HCT, 
hematopoietic stem cell transplantation; RFI, relapse-free interval; CR1, first complete response; SD, standard deviation; NS, not significant.
DISCUSSION
In ALL, karyotypic changes at relapse are considered to 
have poor prognostic implications, such as a poor therapeutic 
response and shorter OS [10, 11]. However, only a few studies 
have investigated the implications of karyotypic changes 
in AML [5]. According to the new ELN prognosis subsets 
recently proposed by an expert panel [1], patients with early 
relapse (i.e., duration of first CR, ＜6 months), adverse cyto-
genetic findings at diagnosis, older age, or previous HCT 
are more likely to have a poor outcome, and, at present, 
the prognostic impact of karyotypic changes at relapse com-
pared with the impact of the karyotype at diagnosis is not 
clear. In this study, we observed karyotypic changes in 17 
of 45 (38%) patients, although karyotypic changes have been 
reported to occur in approximately 60% of AML patients 
[12]. No significant association was found between kar-
yotypic change and RFI in this study, in contrast to the 
other findings [11]. In the present study, adverse karyotypes 
at relapse were more frequent in group 1 than in group 
2, because the most common pattern of karyotypic change 
at relapse was the complex type that involved additional 
aberrations to those present at diagnosis. This finding is 
consistent with previous reports on AML [5]. In our study, 
HCT before relapse was more frequent in group 1 than in 
group 2 (52.9% vs. 82.1%, P=0.036). According to another 
report [13], karyotypic change, particularly clonal evolution, 
is common at relapse after allogeneic transplantation in acute 
leukemia patients.
In this study, we identified potential prognostic factors 
for relapsed AML patients using clinically relevant para-
meters. The karyotype is universally recognized as the best 
prognostic factor for AML [8, 14, 15]. This was confirmed 
by univariate analysis in our patients, for whom karyotypic 
grouping at relapse was the main prognostic factor in terms 
of OR and EFS rather than in terms of OS. However, multi-
variate analysis showed that karyotypic grouping at relapse 
was not associated with OR or EFS. Previously, RFI has 
been considered as the major prognostic determinant after 
relapse [16, 17]. We divided patients who showed first relapse 
into 3 groups according to length of RFI (＜7.5 vs. ≥7.5 
months) and compared OR, OS, and EFS. These results were 
similar to those of other studies. Other important clinically 
prognostic factors for relapsed AML are patient age at relapse 
and prior HCT history [1]. In our study, patients who were 
older at relapse (≥49 years) had a lower OS, but this trend 
did not prove to be significant in multivariate analysis. 
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Table 3. Univariate analysis of potential prognostic factors.
Rate (%) OR P
OS
P
EFS
P
Age at relapse, years 0.167 0.033 0.072
    <49 39.7
    ≥49 60.3
Type NS NS 0.025
    De novo 82.8
    Secondary 17.2
No. of induction cycles to achieve CR1 NS NS NS
    1 86.2
    ≥2 13.8
RFI from CR1, months NS NS NS
    ＜7.5 50
    ＞7.5 50
HCT before relapse NS NS 0.055
    Yes 74.1
    No 25.9
Cytogenetic findings at diagnosis 0.098 0.147 0.101
    Favorable 17.2
    Intermediate 58.6
    Unfavorable 17.2
    NE 6.9
Cytogenetic findings at relapse 0.030 0.070 0.028
    Favorable 6.9
    Intermediate 50.0
    Unfavorable 22.4
    NE 20.7
Karyotypic change between diagnosis and relapse 0.014 0.004 0.010
    Yes 23.3
    No 38.4
    NE 17.8
Salvage regimen 0.039 0.044 0.064
    Ara-C/Anthra-based 12.1
    MEC-based 70.7
    Others 17.2
Abbreviations: OR, overall response; OS, overall survival; EFS, event-free survival; CR1, first complete remission; No., number; RFI, 
relapse-free interval; HCT, hematopoietic stem cell transplantation; NE, not evaluated; NS, not significant.
Fig. 1. (A) OS in AML patients with and without karyotypic change between diagnosis and relapse. The 2 groups (P=0.004) showed significant 
differences in OS. (B) EFS in AML patients with and without karyotypic change between diagnosis and relapse. Karyotypic change was significantly 
associated with EFS after relapse (P=0.010). a)Cases with changed karyotypes between diagnosis and relapse; b)Cases without changed karyotypes 
between diagnosis and relapse. Abbreviations: AML, Acute myeloid leukemia; OS, overall survival; EFS, event-free survival.
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Table 4. Comparison of prognostic factors by multivariate analysis.
OR OS EFS
Odds ratio P HR P HR P
Age at relapse, years
    ＜49 vs. ≥49 0.101 0.503 0.095 6.137 1.047 0.936
Cytogenetic findings at diagnosis
    Fav. and Int. vs. Unfav. 0.088 0.549 0.541 1.842 1.078 0.836
Cytogenetic findings at relapse
    Fav. and Int. vs. Unfav. 0.134 0.261 0.191 1.287 0.729 0.253
Karyotypic change between diagnosis and relapse
    Yes vs. No 0.217 0.217 2.655 0.023 2.831 0.033
Salvage regimen
    MEC-based vs. Ara-C/Anthra-based and others 0.123 0.226 0.925 0.600 0.874 0.447
Type
    De novo vs. Secondary 1.617 0.351
HCT before relapse
    Yes vs. No 0.572 0.344
Abbreviations: OR, overall response; OS, overall survival; EFS, event-free survival; HR, hazard ratio; Fav., favorable; Int., intermediate; Unfav., 
Unfavorable; HCT, hematopoietic stem cell transplantation.
Karyotypic change between diagnosis and relapse was noted 
in 23% of cases, no change was noted in 48% of cases, 
and the remaining cases could not be evaluated. Karyotypic 
change between diagnosis and relapse significantly influ-
enced OR (P=0.014), OS (P=0.004), and EFS (P=0.010). The 
importance of karyotypic changes for prognosis is further 
supported by a study showing that aberrations detected at 
relapse influence patient outcome to a greater extent than 
aberrations detected at diagnosis [5]. Most karyotypic 
changes at relapse were noted in cases that had been included 
in the intermediate karyotypic group at diagnosis and were 
of the complex type (unfavorable karyotypic group) at 
relapse. In cases with complex karyotypes at diagnosis, the 
karyotype at relapse was still complex (same aberrant kar-
yotype plus additional aberrations at relapse and fewer but 
similar aberrations plus new aberrations at relapse compared 
to diagnosis).
In conclusion, despite its retrospective nature and the 
small number of patients, our study indicates that karyotypic 
change between diagnosis and relapse can be adapted to 
predict CR outcomes and tailor routine clinical and biological 
therapeutic strategies for relapsed AML patients.
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